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1. Introduction 
Bacterial meningitis is generally a devastating infection of the leptomeninges and 
underlying subarachnoid cerebrospinal fluid with a high mortality rate, particularly in the 
perinatal and neonatal infant. This is more worrisome because despite the more available 
potent antimicrobials and variably effective vaccines, the disease remains a significant cause 
of morbidity and mortality. Mortality rates could be as high as between 25 - 50% depending 
on which series as well as the area of practice, whilst morbidity, often neurologic, could be 
as elevated as 25 – 45%.  
Many clinical and etiologic studies performed over the recent decades have demonstrated 
that different species of bacteria can precipitate Neonatal-Perinatal bacterial meningitis. 
Streptococcus agalactiae, Staphyloccocus aureus, Group B β-Haemolytic streptococci [GBS], Gram-
negative bacilli, Haemophilus influenzae type b, Neisseria meningitides, Listeria monocytogenes 
and Streptococcus pneumoniae have all been implicated as etiologic pathogens. The ranking 
profile of the major causative organisms, however, depends majorly on the region of 
practice. 
The major burden of Neonatal-Perinatal bacterial meningitis occurs in the developing 
world, however, most evidence derives from wealthy countries even though the spectrum of 
disease, etiology and prognosis may differ.  
In this Chapter, we would dilate on the available evidence of Neonatal-Perinatal bacterial 
meningitis in developing countries; provide its detailed pathophysiologic process/pattern; 
describe the relevant clinical features at presentation; discuss its diagnosis and management 
strategy with particular highlights of adjuncts of steroids; indicate relevant differences from 
well-resourced settings; provide relevant lacunae in knowledge and comment on feasible 
preventive methods.  
2. Incidence of disease 
Bacterial meningitis is undoubtedly more common in the neonatal-perinatal period than at 
any other time in life. This newborn’s gloomy feature of increased susceptibility to infection 
is due to its innate immature immune system that is deficient in humoral and cellular 
immune responses in phagocytic and in complement functions. In the developed\affluent 
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world, mortality has dropped from nearly 50% in the 1970s to <10% currently, but 
morbidity, however, remains substantial, with 20–58% of survivors developing serious 
neurological sequelae, such as deafness.  
Most worrisome is the fact that its incidence, mortality and morbidity in the developing 
world have remained unacceptably high; variably reported as between 40–58%. With a 
documented incidence of 6.5\1000 live births, the disease has shown a rising trend in 
Nigeria as against other more affluent regions maintaining relatively stable rates of less than 
1\1000. 
3. Etiopathogenesis  
The chance of occurrence of bacterial meningitis becomes highly likely in the newly born 
baby with presence of adverse risk factors. These risk factors can generally be grouped into 
Prenatal, Intrapartum, Natal or Postnatal categories; or into Maternal, Obstetrics, or 
Postpartum divisions. These include low birth weight [LBW], very low birth weight [VLBW] 
and preterm gestation; maternal risk factors of premature ruptures of membranes, 
prolonged rupture of membranes (> 24 hours), maternal colonisation with Group B 
Streptococcus (GBS), maternal chorioamnionitis, maternal peripartum pyrexia and low 
socioeconomic status. These factors are universally important and well recognized. Table 1 
illustrates some of these factors. 
 
Table 1. Some well known predisposal risk factors to the occurrence of Neonatal-Perinatal 
meningitis. 
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4. The main pathogens of disease 
The commonly involved pathogens of Neonatal-Perinatal bacterial meningitis often differ 
from community to community, region to region and continent to continent. The pathogens 
also frequently correlate with the degree of development, advancement and environmental 
hygiene, and thus what we encounter in the developing world differs from that of the 
developed\affluent world. In developed countries, the predominant pathogens identified 
from cerebrospinal fluid [CSF] are GBS, Escherichia coli, Listeria monocytogenes, other 
 
www.intechopen.com
 
Meningitis 24
 
*Abbreviations: Refs – References, Yr – Year, Pts – Patients, WHO – World Health Organization, N.A. – 
Not Available, FT – Full Term, RCT – Randomized Control Trial, +ve – Positive, WCC – White cell 
count, CSFs – Cerebrospinal fluids.  
Table 2. Etiology of neonatal bacterial meningitis in developing countries  
Gram-negative enteric bacteria and Streptococcus pneumoniae. Infections in the neonatal 
period are frequently divided into ‘early onset’, (first 5–7 days, implying vertical 
transmission) when frequently isolated bacteria include GBS, E. coli and Listeria 
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monocytogenes, and ‘late onset’, (after the first week of life, implying nosocomial or 
community acquired infection), when common organisms include Gram negative 
organisms, staphylococci and GBS. 
However, in the developing world, the pathogen profile appears different with most studies 
isolating Staphylococcus aureus and other gram negative organisms as leading culprits. 
Although the rate of isolates of Escherichia coli and Klebsiella aeruginosa are similar between 
the developed and developing regions of the world, however, there remains a very 
significant less encounter with GBS in the latter.  
The speculated reasons for this difference are multi-factorial, and could include cultural 
difference in modes of genital care, population differences in colonisation, genetic 
differences in immune response and possibly geographic differences in laboratory 
techniques for pathogen isolation and reporting. Table 2 highlights the pathogen profile and 
pattern of Neonatal-Perinatal meningitis in developing countries.  
A good evaluation was a WHO-supported multi-centre study [covering Ethiopia, The Gambia, 
Papua New Guinea and the Philippines], but it only attempted to determine etiological agents 
responsible for serious infections in young infants [≤90 days]. However, this study was limited 
by identifying only 40 cases of neonatal meningitis, and the findings varied immensely 
between centres, which narrowed the conclusions that could be drawn. It is pertinent that 
unusual pathogens were identified in some other studies, e.g. Neiseria Meningitidis, 
Haemophilus Influenzae type b, and Salmonella typhimurium. Table 2 is particularly worthwhile 
as it demonstrates the geographic differences of causal pathogens of Neonatal-Perinatal 
meningitis, which could serve as good guide to empirical antibiotic therapy. 
5. Pathophysiology  
Method of acquisition: Meningitis is basically an infection of the meninges (membranes 
that surround the brain and spinal cord) that enters through the bloodstream from other 
parts of the body. Meningococcal disease was first described as early as 1805, when an 
outbreak spread through Geneva, Switzerland. However, it was not until 1887 that a 
causative agent of meningococcal meningitis was identified. The pathogens that cause 
bacterial meningitis are very common and live naturally in the back of the nose and 
throat.At any given time, 10% of the populations are carriers of the disease but never 
actually become sick. In fact, most cases of meningitis are acquired through exposure to 
asymptomatic carriers. 
Meningitis can be spread via nose and throat secretions [e.g. coughing, sneezing]. However, 
meningitis is not considered to be a highly contagious disease. Casual contact or breathing 
in the air where a person with meningitis has been normally would not expose someone to 
meningitis because the causative organisms cannot live outside the body for much long to 
allow their survival. 
Acute bacterial meningitis usually develops from an invasion of bacterial pathogens from 
mucosal surfaces in nasopharynx, sinus cavities, and middle ear space into the blood 
stream. It can also result from head injuries, penetrating wounds, or neurologic surgeries. 
In neonatal-perinatal infants, mother-to-infant transmission and aspiration of intestinal and 
genital tract secretions during labour and delivery are common modes of transmission.  
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However, the most implicated mode of acquisition of infection is via the haematogenous 
route in preponderant cases worldwide. 
Pneumococcal meningitis usually arises in the setting of sustained bacteraemia that permits 
bacterial penetration across the blood-brain barrier and into the subarachnoid space. Once 
present in the central nervous system, bacterial multiplication incites host cell toxicity and 
release of a broad range of cytokines [e.g., Interleukin-1, Interleukin-6, and Tumour Necrosis 
Factor-α] that increase inflammation and vascular permeability. This is the same pattern 
with the other meningitis-causing pathogens. The resulting injury to the cerebral 
microvasculature causes brain edema that in turn leads to intracranial hypertension. Unless 
treated, this process usually leads to mortality and\or increased morbidity, such as neural 
deafness. 
The importance of S. pneumoniae as a cause of childhood meningitis has been well described. 
S pneumoniae is also by far the most common pathogen recovered from community- 
acquired recurrent meningitis, accounting for a majority of cases of recurrent meningitis, 
even in the newborn infant. The overall case-fatality rate is close to 30%. 
H. influenzae type b meningitis, once the most prevalent form of meningitis in children, is 
now rarer in the developed world because of successful immunization practices [H. 
influenzae type b conjugates vaccine) in the past 2 decades. In fact, incorporation of this 
vaccine into the routine immunization schedule resulted in a 94% decline in the number of 
cases of meningitis caused by H. influenzae type b in developed countries. 
5.1 Detection of cases  
The meninges have no host defenses to fight off invading organisms. One of the most 
important things to determine when meningitis is suspected is whether it is bacterial or 
viral. If a bacterial pathogen is the culprit, it is essential to identify the specific causative 
agent so that the appropriate antibiotics can be prescribed immediately. If left untreated, 
bacterial meningitis can lead to severe complications such as brain damage, hearing loss, 
epilepsy and death. Viral meningitis on the other hand, is generally less severe and typically 
resolves on its own. 
The specific diagnosis of Neonatal-Perinatal bacterial meningitis remains protean and 
problematic. Its identification generally depends on a high index of suspicion. Clinically, the 
disease is often subtle and indistinguishable from that a metabolic problem or any illness 
solely due to sepsis, and without meningitis. The symptoms commonly include, lethargy, 
fever – which is better described as temperature instability, excessive crying with difficulty 
at being consoled, irritability, poor feeding, apprehension, and subtle and\or frank neonatal 
seizures. Neck stiffness or nuchal rigidity is often not detectable because of relative 
immaturity of the cranio-spinal nerve bundles with deficient myelination, but may rarely be 
present. Other problems are bulging anterior fontanelle, opistothonic posturing and any 
other non-specific neurological features. 
Positive culture of CSF remains the gold standard for diagnosis and should be performed on 
all neonates where sepsis is suspected unless a contraindication exists. However, in view of 
the anatomic immaturity of the blood-brain-barrier area, caution should be employed when 
interpreting CSF parameters in the premature neonate. 
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Gram stains of CSF may could also provide useful information, even if CSF culture is not 
available. Simultaneous blood cultures are often positive in 40–80% of cases. Furthermore, it 
is notable that Neonatal-Perinatal meningitis can be present even in the absence of CSF 
pleocytosis, and CSF protein and glucose levels are age related. The simultaneously assessed 
CSF:Blood glucose relationship should not be less than 50% in any neonate, and solely 
detected hypoglycorracia [CSF sugar of 0-<1.3mmol\L] is always diagnostic.  
5.2 Diagnostic methods  
Early diagnosis of Neonatal-Perinatal bacterial meningitis is very crucial. Because the 
symptoms of meningitis can closely mimic other viral illnesses, many clinicians miss the 
diagnosis and prescribe inappropriate treatments. In many cases, a missed diagnosis can have 
fatal consequences. All healthcare givers should be aware that early recognition of the 
symptoms can be a matter of life and death, and they should become familiar with all possible 
signs and symptoms. A careful and thorough diagnostic work-up must be undertaken. 
A detailed work-up line is shown in Table 3. The specific microbiological culture procedure 
of all major fluid areas of the body, i.e. blood, CSF and urine should be performed. This is 
often referred to as a ‘Panculture Procedure’, and has the value of identifying those neonates 
or perinates that could have a concomitant septicaemia and nephritis [UTI]. This is vital and 
highly needed since it has been well documented in several reports, that as highly as 30% of 
newborn infants with septicaemia also have concomitant meningitis.  
The CSF must be examined for general appearance, consistency, and tendency to clot. CSF 
analysis should include cell counts (including a WBC differential), glucose and protein 
analysis, and Gram staining of the centrifuged sediment. The use of C-reactive protein 
[CRP] levels has been shown to play an important role in differentiating among the various 
types of meningitis. More recently, some workers recommended the use of serum 
procalcitonin level for better diagnostic and prognostic value than CRP or leukocyte count 
to distinguish between bacterial and viral meningitis. Their cases were, however, older 
children of 4months and above. It requires validation in the neonate and perinate. 
Polymerase chain reaction has remained sensitivity and quick in detecting and 
differentiating between viral and bacterial meningitis. 
The hands, ears, nose, throat and sinuses should be checked for the possible source of 
infection, and a latex agglutination test to detect bacterial antigens of Staphylococcus aureus, 
Streptococcus pneumoniae, Neisseria meningitides, Haemophilus influenzae type b, Group B 
Streptococcus, Klebsiella sps and Escherichia coli strains, can aid in the diagnosis of Neonatal-
Perinatal bacterial meningitis. However, this test may lack sensitivity unless ultrasonic 
enhancement is used. 
Newborn infants with suspected bacterial meningitis should also undergo testing for glucose, 
serum electrolytes and blood urea nitrogen, which could indicate the degree of dehydration 
and identify hyponatraemia and hypoglycaemia; common symptoms of meningitis. 
Clinical clues signaling the presence of bacterial meningitis may include sinusitis, otitis, 
mastoiditis, infective endocarditis and characteristic skin infections [such as those seen in 
infections caused by herpes, simplex virus, varicella-zoster virus]. Cardiovascular instability 
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or focal neurologic signs such as papillary changes, hemi-paresis, and ocular palsies are 
indicative of bacterial meningitis. Patechial and purpuric rashes usually indicate 
meningococcemia or H. influenzae meningitis. Presence of arthritis may suggest the presence 
of H. influenza and N. meningitides, and head trauma or a chronically draining ear usually 
signals pneumococcal meningitis. 
 
Table 3. Tests commonly utilized in the diagnosis of Neonatal-Perinatal bacterial meningitis  
Bacterial meningitis in the newborn can be difficult to distinguish from other infectious 
diseases. To aid in the differential diagnosis, physicians should take a complete 
epidemiologic history, including contact with sick persons; maternal dietary habits, and\or 
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illicit drug use; medication history; exposure to insects, rodents, or arthropods; and recent 
travel history. 
Major epidemic of meningitis frequently occur during the hot dry seasons. Sub-Saharan 
Africa is plagued by the highest meningitis [N. meningitides] disease burden, is usually 
referred to as the “meningitis belt”. 
5.3 Treatment intervention 
It cannot be overemphasized that treatment must be started early in the course of the 
disease, especially as it is of bacterial aetiology. Prompt intervention can reduce the risk of 
death to below 15%. If not treated as a medical emergency, bacterial meningitis can lead to 
seizures, coma, increased intracranial pressure, nerve damage, stroke and even death. 
By identifying the causative agent, the appropriate antibiotic can be administered. The 
baby’s age, co-morbidities and the status of his or her immune system can aid in this 
identification. For example, immunocompromised patients are at particular risk for infection 
with S. pneumoniae, N. meningitidis, Listeria monocytogenes, and aerobic Gram-negative bacilli. 
In the developing countries, S. aureus remains a highly predominant organism in the 
neonatal age, whereas GBS is rarely encountered. Antibiotic intervention only improves the 
baby’s prognosis if the antimicrobial therapy is administered before the patient’s clinical 
condition has deteriorated. If antibiotics are started when the baby is already in an advanced 
stage of the disease, the chances of survival is poor. 
Administration of antibiotics can also protect the development of the disease among 
children, or parents who have been exposed to another case of meningitis. According to 
some investigators, giving the appropriate antibiotics to household contacts of the patient 
with meningococcal disease can reduce their risk of infection by 89%. Antibiotic therapy 
must be effective against common causative pathogens and must achieve adequate 
bactericidal activity without toxicity in the CSF. Most often used antibiotics include; 
ampicillin or penicillin and an aminoglycoside [e.g. Gentamicin] or a third-generation 
cephalosporin, such as ceftriaxone or cefotaxime. The recommendation of ceftriaxone 
includes the awareness that it may cause billiary sludge leading to jaundice in the neonate. 
Such caution appears to be theoretical, as in practice, the problem rarely occurs. Penicillin 
and gentamicin are widely available, cheap and the first line antimicrobial therapy in many 
resource-poor settings. In developed countries, initial therapy often includes some 
combination of three agents: Penicillin, an aminoglycoside and a third-generation 
cephalosporin – considered by some school-of-thought to be over use and miss use of 
antibiotics.  
First-line therapy is usually either ampicillin and gentamicin or ampicilin and cefotaxime, or 
ceftriaxone and gentamicin. The value of the cephalosporins is their widely spaced dosage 
regimen with satisfactory better compliance. The use of cephalosporins has coincided with a 
reduction in mortality from neonatal meningitis in developed countries but with no 
associated fall in morbidity.  
Gentamicin remains an effective antimicrobial, despite its small therapeutic window. 
Despite the fears of its causing renal toxicity and deafness, there is no documented 
occurrence of these complications during clinical use. 
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Third-generation cephalosporins (cefotaxime and ceftriaxone) are active against the major 
pathogens of neonates worldwide, including aminoglycoside-resistant strains. They have 
good CSF penetration and achieve adequate therapeutic concentrations in the CSF. Third-
generation cephalosporings were recommended in the multi-centre WHO study group of 
serious infections in young infants.  
If available, vis-à-vis a resource-poor setting, cefotaxime and ceftriaxone are currently 
recommended for use in Neonatal-Perinatal bacterial meningitis in view of the added 
advantage of a longer half-life, allowing less frequent administration.  
However, it is pertinent that empiric antibiotic choice should be tailored to local 
epidemiology, early versus late infections and whether the infection was nosocomially 
acquired.  
5.4 Adjunctive therapy 
The use of corticosteroids as an adjunct to antibiotic therapy has been shown to render 
treatment of bacterial meningitis more effective, especially in children by reducing CSF 
inflammation and hearing loss. This has been shown conclusively for disease caused by H. 
influenzae type b and S. pneumoniae and it is, therefore, now routinely used worldwide. Its 
efficacy is said to improve if administered before, or along with the antibiotics. Though few 
studies have documented the valuable effects of steroids [dexamathasone] as an adjunct in 
neonatal meningitis, more evaluation requires to be done without timidity or over anxiety 
by clinicians. Table 4 elucidates the improved outcome with its use in Nigeria. 
 
 
* The disabilities and handicaps were: hearing-defects, subdural effusion, hydrocephalus, hemiparesis 
and recurrent afebrile seizures.  
Table 4. Value of steroids (dexamethasone) and quality of recovery from Neonatal-Perinatal 
bacterial meningitis. 
There was significant less mortality and improved full recovery with adjunctive use of 
steroids, p=0.006. 
5.5 The interplay of bacterial resistance 
Penicillin resistance is mediated by alterations in penicillin binding proteins (PBPs). PBPs 
are membrane-bound enzymes that catalyze the terminal steps in the assembly of the 
bacterial cell wall. The key PBPs involved in penicillin susceptibility includes PBP 1a, 1b, 2a, 
2b, and 3. Strains with reduced susceptibility to penicillin also exhibit reduced susceptibility 
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to beta-lactam drugs such as cephalosporins. S. pneumoniae resistance to other antibiotic 
classes is also now widespread, and includes resistance to macrolides, trimethoprim-
sulfamethoxazole, chloramphenicol, and quinolones. Multiple mechanisms mediate 
resistance and are briefly described in Table 5. Drug resistance to a single class of antibiotics 
may also be mediated by multiple mechanisms. Acquired resistance to a particular class of 
antibiotics increases the likelihood that the strain will be resistant to other classes of 
antibiotics. For example, 94% penicillin-susceptible strains of S. pneumoniae were recently 
found to be susceptible to azithromycin, but 17% of penicillin-resistant strains were 
azithromycin-susceptible. 
Resistance to macrolides, and trimethoprim-sulfamethoxazole is also widespread. 
Macrolides resistance is mediated by either an efflux pump [low-level resistance] or a 
ribosomal methylase [high-level resistance]. 
Penicillin-resistant strains are often resistant to cephalosporins such as ceftriaxone and 
cefotaxime. Vancomycin is active against all strains of S. pneumoniae but vancomycin-
tolerant strains have now been described. The individual members of the flouroquinolone 
class demonstrate differential activity against S. pneumoniae. 
 
 
Table 5. Mechanisms of antibiotic resistance of S. pneumoniae 
6. Conclusion  
It is intriguing that Neonatal-Perinatal bacterial meningitis continues to be a major cause of 
morbidity and mortality in the developing world. It is vital that more efforts are required for 
its control rather the offer of appropriate diagnosis and treatment. It is majorly necessary 
that efforts must be directed to community health education, provision of regular 
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information, and a versatile up-keep of hygiene and routine cleanliness. The importance of 
immune boosting through vaccinations and their acceptance is further worthy, as 
prevention is always better than cure. Important differences in aetiology have been noted 
but early and focused treatment of established disease, with the use of steroid adjunct, 
remains essential.  
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